Indications for Cabergoline:
Hyperprolactinemic disorders, either idiopathic or due to pituitary tumors.
Initially 0.25mg twice weekly. Dose may be increased at 4-week intervals by 0.25mg twice weekly. Max: 1mg twice weekly.
Uncontrolled hypertension. Sensitivity to ergot alkaloids.
Not for pregnancy-induced hypertension or postpartum lactation inhibition or suppression. Respiratory or cardiac disease due to fibrosis. Hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers: not recommended.
Concurrent dopamine D2 antagonists (eg, phenothiazines, butyrophenones, thioxanthines, metoclopramide): not recommended. Hypotension may be potentiated by antihypertensives.
GI upset, dizziness, fatigue, postural hypotension, nervousness, breast pain, dysmenorrhea, vision abnormalities; rare: fibrosis, valvulopathy.
Formerly known under the brand name Dostinex.